Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cerivastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 2/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | PDE4A | P27815 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cerivastatin SCHEMBL15263415 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL31517662 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL28019013 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL41888 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL41887 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL19518120 | 0.97 | HMGCR (0.80) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL2900117 | 0.97 | HMGCR (0.90) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL6633443 | 0.94 | HMGCR (0.75) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL15686549 | 0.91 | HMGCR (0.86) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL13890391 | 0.91 | HMGCR (0.86) | HMGCRESR1CHRM1TBXA2RPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009021113-A1 | METHODS FOR ENHANCING GLUTAHIONE PEROXIDASE ACTIVITY | HOLTZMAN, JORDAN, L. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20060034831-A1 | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors | WYETH | 2006-02-16 | — | — | US | disclosed |
| WO-2005046675-A2 | METHODS FOR ENHANCING GLUTATHIONE PEROXIDASE ACTIVITY | HOLTZMAN JORDAN (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034831-A1 | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors | DPP8, IGFBP1, IGFBP5 | HMGCR 634/4885ESR1 3100/4885CHRM1 4588/4885 |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | PTPN6, PTPN1, PNLIP | HMGCR 53/4885ESR1 3153/4885CHRM1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.